🇺🇸 FDA
Patent

US 7189513

Human papilloma virus immunoreactive peptides

granted A61KA61K2039/57A61K2039/6006

Quick answer

US patent 7189513 (Human papilloma virus immunoreactive peptides) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Mar 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Mar 13 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/57, A61K2039/6006, A61K39/00, A61P